Compare · CELL vs PM
CELL vs PM
Side-by-side comparison of PhenomeX Inc. (CELL) and Philip Morris International Inc (PM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and PM operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM carries a market cap of $300.80B.
- PM has hit the wire 6 times in the past 4 weeks while CELL has been quiet.
- PM has more recent analyst coverage (25 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Philip Morris International Inc
- Price
- $1.00+0.14%
- $192.99+0.94%
- Market cap
- -
- $300.80B
- 1M return
- -
- +7.96%
- 1Y return
- -
- +22.35%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest PM
- SEC Form 10-Q filed by Philip Morris International Inc
- BTIG Research initiated coverage on Philip Morris International with a new price target
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
- Philip Morris International to Host Webcast of 2026 Second-Quarter and First Six-Months Results
- Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PMI U.S. Unveils the ZYN America250 Art Series, Bringing Modern Culture to Limited-Edition Cases
- FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products
- Americans Are Losing Patience with Innovation That Doesn't Make Life Better, New Poll from PMI U.S. Finds
- Philip Morris International Inc filed SEC Form 8-K: Other Events